Supplementary Figure S5 from Quantitative Protein Expression of Antibody–Drug Conjugate Targets in EGFR Mutated and Wild-type Non–Small Cell Lung Cancer
Year: 2025
Type: supplementary-materials
Abstract: Survival Kaplan-Meier estimates on the EGFR-TKI treated cases of the EGFRmut non-small cell lung cancer cohort according to ‘low’ and ‘high’ A) HER2, B) TRO2, C) HER3, and D) EGFR expression.
Authors: Ioannis P. Trontzas, Mengni He, Anna Wurtz, Charles J. Robbins, Nathaniel Robinson, Katherine Bates, Matthew Liu, Thazin N. Aung, Liam Scott, Nay Chan, Sneha Burela, Jacob Schillo, Daniel C. Liebler, Salisha Hill, Ryan D. Morrison, Ioannis Vathiotis, Konstantinos N. Syrigos, Sarah B. Goldberg, Katerina Politi, David L. Rimm
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4411907755